The North America Apheresis Market would witness market growth of 7.5% CAGR during the forecast period (2022-2028).
The key factors driving the apheresis market growth include increased demand for blood components globally and a surge in government blood donation initiatives. Furthermore, newly approved indications for apheresis treatment, such as autoimmune hemolytic anemia, acute disseminated encephalomyelitis, and cardiac neonatal lupus, contribute to market growth.
Good epidemiologic studies estimate of the prevalence (and incidence, where possible) of infectious markers in the general population, combined with an effective donor education, motivation, and recruitment policy to recruit new voluntary nonremunerated blood donors from these populations, is the key to recruiting and retaining safe blood donors. The retention of blood donors is influenced by a nice atmosphere in the blood bank, good donor care, and polite and effective interaction between personnel and donors.
The increasing number of diseases, an increase in the demand for blood and its elements and associated protection, technological development in the creation of new apheresis techniques, and increased reimbursement policy initiatives and financial support for apheresis procedures are all driving the growth of the apheresis market.
Apheresis is a technique that uses computerized machinery to remove a particular blood component from a patient. It is typically used to treat over 30 different disorders in Canada, and in 2002, over 7 million Canadian dollars was spent on 8600 plasma exchange treatments. The Canadian Apheresis Group (CAG) is a national volunteer organization of physicians and nurses who are interested in determining whether therapeutic apheresis should be used (TA).
It was established in 1980 under the auspices of the Department of National Health and Wellbeing with the objectives of providing a forum for information exchange among Canadian apheresis practitioners and continuing to develop statistically significant sound, evidence from clinical testings to test the efficacy of plasma exchange as a treatment for various disorders. Representatives from each of Canada's main medical centers are part of the organization, which serves as a link between the CAG and local hospital communities around the country.
The US market dominated the North America Apheresis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,083.4 million by 2028. The Canada market is experiencing a CAGR of 10% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 9% during (2022 - 2028).
Based on Procedure, the market is segmented into Donor/Automated and Therapeutic. Based on Product, the market is segmented into Disposable & Reagents, Devices, and Software. Based on Method, the market is segmented into Centrifugation, Membrane Separation, and Selective Adsorption. Based on End User, the market is segmented into Blood Centers, Hospitals, and Others. Based on Component, the market is segmented into Plasma (Plasmapheresis), Platelets (Plateletpheresis), Leukocytes (Leukapheresis or leukopheresis), Lymphocytes (Lymphopheresis or lymphapheresis), and RBC's (Erythropheresis). Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Apheresis Market is Estimated to reach $4 Billion by 2028, at a CAGR of 8.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Asahi Kasei Medical Co., Ltd., Kaneka Corporation, Cerus Corporation, B. Braun Melsungen AG, Nikkiso Co., Ltd., Charles River Laboratories International, Inc., and SB Kawasumi Laboratories, Inc.
By Procedure
By Product
By Method
By End User
By Component
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 